CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is a randomized, double-blind, sham-controlled, adaptive-design pivotal study of sensory stimulation in subjects with mild to moderate Alzheimer's...
Phoenix, Arizona, United States and 67 other locations
This study is designed to evaluate safety and efficacy of fosgonimeton (ATH-1017) in the treatment of mild to moderate Alzheimer's disease...
Phase 2, Phase 3
Phoenix, Arizona, United States of America and 89 other locations
The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early Alzheimer's...
Phase 3
Chandler, Arizona, United States of America and 75 other locations
and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndr...
Phase 1, Phase 2
Phoenix, Arizona, United States and 18 other locations
progression of AD, as compared to no stimulation (OFF), by measuring baseline (pre-implantation) to 12-month change in the integrated Alzheimer's...
Phoenix, Arizona, United States and 20 other locations
-323511 among adults with Agitation Associated with Dementia due to Alzheimer's Disease.Part A consists of a Screening Period (up t...
Phase 1
Tempe, Arizona, United States
is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Tri...
Phase 3
Phoenix, Arizona, United States and 117 other locations
be from 2 clinical subgroups: mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild Alzheimer's disease...
Phase 2
Phoenix, Arizona, United States and 168 other locations
This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determin...
Phase 3
Phoenix, Arizona, United States and 246 other locations
A long-term extension study to evaluate the safety, tolerability, and efficacy of AL002 in participants with Early Alzheimer's Disease...
Phase 2
Phoenix, Arizona, United States and 53 other locations
Clinical trials
Research sites
Resources
Legal